

NEW ZEALAND

Number of new cases

38 157

Number of deaths


11 301

Number of prevalent cases (5-year)

123 774


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	2 407 196	2 491 005	4 898 201
Incidence*			
Number of new cancer cases	20 562	17 595	38 157
Age-standardized incidence rate	473.4	386.3	427.3
Risk of developing cancer before the age of 75 years (cum. risk %)	43.0	34.7	38.9
Top 3 leading cancers (ranked by cases)**	Prostate Colorectum Lung	Breast Colorectum Melanoma	Colorectum Breast Prostate
Mortality*			
Number of cancer deaths	6 065	5 236	11 301
Age-standardized mortality rate	112.6	90.0	100.2
Risk of dying from cancer before the age of 75 years (cum. risk %)	11.0	9.1	10.0
Top 3 leading cancers (ranked by deaths)**	Lung Colorectum Prostate	Lung Colorectum Breast	Lung Colorectum Prostate
Prevalence*			
5-year prevalent cases	65 746	58 028	123 774



Top 5 most frequent cancers**

Males




Total: 20 562

Rank	Cancer site	Number of cases	Percent
1st	Prostate	3 769	18.3%
2nd	Colorectum	2 255	11.0%
3rd	Lung	1 659	8.1%
4th	Melanoma	1 547	7.5%
5th	NHL	532	2.6%
-	Others	10 800	52.5%

Number of new cases in 2022, males, all ages

Females




Total: 17 595

Rank	Cancer site	Number of cases	Percent
1st	Breast	3 855	21.9%
2nd	Colorectum	1 815	10.3%
3rd	Melanoma	1 192	6.8%
4th	Lung	1 137	6.5%
5th	Corpus uteri	534	3.0%
-	Others	9 062	51.5%

Number of new cases in 2022, females, all ages

Both sexes



Total: 38 157

Rank	Cancer site	Number of cases	Percent
1st	Colorectum	4 070	10.7%
2nd	Breast	3 855	10.1%
3rd	Prostate	3 769	9.9%
4th	Lung	2 796	7.3%
5th	Melanoma	2 739	7.2%
-	Others	20 928	54.8%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Colorectum	4 070	1	10.7	4.4	1 704	2	15.1	1.3	15 060	307.5
Breast	3 855	2	10.1	10.0	759	4	6.7	1.7	15 934	639.7
Prostate	3 769	3	9.9	10.7	809	3	7.2	0.88	19 014	789.9
Lung	2 796	4	7.3	3.4	2 122	1	18.8	2.3	3 169	64.7
Melanoma	2 739	5	7.2	3.4	449	6	4.0	0.41	10 102	206.2
NHL	951	6	2.5	1.2	383	8	3.4	0.31	3 104	63.4
Leukaemia	823	7	2.2	0.93	413	7	3.7	0.36	2 331	47.6
Kidney	671	8	1.8	0.89	247	14	2.2	0.25	2 110	43.1
Bladder	662	9	1.7	0.65	281	13	2.5	0.19	1 950	39.8
Pancreas	661	10	1.7	0.70	628	5	5.6	0.63	544	11.1
Corpus uteri	534	11	1.4	1.5	156	17	1.4	0.33	2 431	97.6
Stomach	497	12	1.3	0.56	304	10	2.7	0.32	729	14.9
Thyroid	436	13	1.1	0.66	36	22	0.32	0.03	1 438	29.4
Multiple myeloma	410	14	1.1	0.46	236	16	2.1	0.19	1 142	23.3
Oesophagus	396	15	1.0	0.42	302	11	2.7	0.30	512	10.5
Liver	382	16	1.0	0.47	336	9	3.0	0.39	507	10.4
Brain CNS	381	17	1.00	0.54	290	12	2.6	0.40	1 724	35.2
Ovary	378	18	0.99	0.96	238	15	2.1	0.49	1 238	49.7
Lip, oral cavity	359	19	0.94	0.46	103	19	0.91	0.09	979	20.0
Testis	177	20	0.46	0.56	7	31	0.06	0.02	680	28.3
Cervix uteri	149	21	0.39	0.44	63	20	0.56	0.15	510	20.5
Larynx	132	22	0.35	0.18	34	23	0.30	0.04	437	8.9
Mesothelioma	120	23	0.31	0.12	112	18	0.99	0.10	145	3.0
Hodgkin lymphoma	103	24	0.27	0.15	19	26	0.17	0.02	394	8.0
Oropharynx	98	25	0.26	0.15	32	24	0.28	0.04	323	6.6
Gallbladder	73	26	0.19	0.08	63	20	0.56	0.06	89	1.8
Vulva	71	27	0.19	0.14	23	25	0.20	0.03	240	9.6
Salivary glands	37	28	0.10	0.05	11	29	0.10	0.01	121	2.5
Hypopharynx	30	29	0.08	0.04	12	28	0.11	0.01	63	1.3
Nasopharynx	29	30	0.08	0.04	16	27	0.14	0.02	120	2.5
Vagina	22	31	0.06	0.05	11	29	0.10	0.01	71	2.9
Penis	17	32	0.05	0.04	2	32	0.02	0.00	26	1.1
All cancers	38 157	-	-	38.9	11 301	-	-	10.0	123 774	-
All cancers excl. NMSC	27 551	-	-	29.3	11 111	-	-	9.9	90 918	-

Data source and methods

Incidence



Country-specific data source: [{"dt_list": "National cancer registry"}]
 Method: National (or sub-national with coverage greater than 50%) rates projected to 2022

Mortality

Country-specific data source: National (WHO)
 Method: National rates projected to 2022

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

